2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1077

Increased Expression of B-Cell Lipid Rafts in Patients with Primary Sjogren’s Syndrome Correlated Positively with Disease Activity Score, Suggesting a B Cell Activated State Potentially Relevant for the Disease Pathogenesis and Response to Biologic Therapies
Abstract Number: 1078

Elevated Proportion of CD38highIgD+ b Cells in Peripheral Blood Is Related to Disease Activity in Patients with Primary SjöGren’s Syndrome
Abstract Number: 1079

Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease
Abstract Number: 1080

B-Cell Clonal Expansions in Parotid Glands of Sjogren’s Patients Are Associated with Increased Numbers of N-Glycosylation Motifs in the Immunoglobulin Heavy Chain Genes
Abstract Number: 1081

The CRL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Inhibits BAFF-Mediated Plasmablast Differentiation and Immunoglobulin Secretion from Class Switched CD27+IgD- Memory and Lupus-Associated CD27-IgD- Double Negative B-Cells
Abstract Number: 1082

Type I/II Interferon Commits to Abnormal Expression of Chemokine Receptor on B Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 1083

Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Abstract Number: 1084

Antibodies to Native Vimentin in Lupus: Characterization, Isotypes, Origins, and Associations with Other Autoimmune Pathways
Abstract Number: 1085

The Anti-CD38 Monoclonal Antibody TAK-079 Depletes Antibody Secreting Cells from Normal and SLE Patients
Abstract Number: 1086

Analysis of the Naive B Cell Repertoire in Belimumab Treated SLE Patients
Abstract Number: 1087

Nonmemory B Cell Signature Alterations in Belimumab Patients
Abstract Number: 1088

Expansion of Transitional B Cells in SLE Patients Correlates with Increased Toll-like Receptor 7 Expression
Abstract Number: 1089

Decreased B Cell Activation-Induced Apoptosis in Cells Overexpressing Interferon Regulatory Factor 5 (IRF5), a Gene Associated with Risk for Systemic Lupus Erythematosus and Other Autoimmune Diseases
Abstract Number: 1090

CpG-Stimulated B Cells Require Glutaminolysis for Glycolysis, Mitochondrial Respiration, and Cytokine Production
Abstract Number: 1091

Synergistic Immunoregulatory Effects of IL-10 and TGF-β on Humoral Immunity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].